scholarly journals Fogarty-assisted flow redirection during conventional transarterial chemoembolization for caudate lobe hepatocellular carcinoma

2022 ◽  
Vol 6 ◽  
pp. 1
Author(s):  
Darrel Ceballos ◽  
Albert Tine ◽  
Rakesh Varma ◽  
Husameddin El Khudari
Keyword(s):  
Hepatocellular Carcinoma ◽  
Transcatheter Arterial Chemoembolization ◽  
Caudate Lobe ◽  
Fogarty Catheter ◽  
Proper Hepatic Artery ◽  
Liver Malignancy ◽  
Embolic Material ◽  
Extreme Variation ◽  
Arterial Chemoembolization

Hepatocellular carcinoma (HCC) is the most common primary liver malignancy. Approximately 8% of patients with HCC are not suitable candidates for curative options. Caudate lobe HCC presents technical challenges for interventional radiologists. Caudate lobe HCC has higher local recurrence and poorer survival rate than other segments. Transarterial treatments of caudate HCC are difficult due to extreme variation of arterial supply. We present a case of a caudate lobe HCC with supply from the proper hepatic artery, which underwent successful conventional transcatheter arterial chemoembolization (cTACE) by utilizing a Fogarty catheter to direct the embolic material. The patient presented 5 days following the procedure with duodenitis and pancreatitis, which were managed conservatively. Follow-up imaging at 1 month showed significant improvement of the ischemic duodenitis/pancreatitis with successful cTACE.

Transcatheter Arterial Chemoembolization in Inoperable Hepatocellular Carcinoma: Four-year Follow-up

1996 ◽  
Vol 7 (3) ◽  
pp. 419-425 ◽  
Author(s):  
Henry Ngan ◽  
Ching-lung Lai ◽  
Sheung-tat Fan ◽  
Edward C. Lai ◽  
Wai-key Yuen ◽  
...  
Keyword(s):  
Hepatocellular Carcinoma ◽  
Transcatheter Arterial Chemoembolization ◽  
Arterial Chemoembolization

scholarly journals Diffuse Infiltrative Hepatocellular Carcinoma with Portal Vein Tumor Thrombosis Completely Cured by Transcatheter Arterial Chemoembolization: Case Report with 8-Year Follow-Up

2016 ◽  
Vol 10 (3) ◽  
pp. 623-628 ◽  
Author(s):  
Suk Bae Kim
Keyword(s):  
Hepatocellular Carcinoma ◽  
Portal Vein ◽  
Transcatheter Arterial Chemoembolization ◽  
Treatment Options ◽  
Common Type ◽  
Portal Vein Tumor Thrombosis ◽  
Diffuse Type ◽  
Tumor Thrombosis ◽  
Arterial Chemoembolization

Hepatocellular carcinoma (HCC) is the most common type of liver cancer and its treatment options are determined by shape, liver function, loci, and stages of cancer. Diffuse type of infiltrative HCC accompanied by portal vein tumor thrombosis (PVTT) has the poorest prognosis among other HCCs and there are no other prominent treatment options than systemic chemotherapy. In this study, we report a case of a 56-year-old man with diffuse infiltrative HCC accompanied by PVTT who achieved complete remission for 8 years after receiving conventional transcatheter arterial chemoembolization using adriamycin and gelfoam.

scholarly journals Evaluation of doxorubicin-eluting bead transcatheter arterial chemoembolization combined with endovascular brachytherapy for hepatocellular carcinoma with main portal vein tumor thrombus

2020 ◽  
Author(s):  
Zhiyuan Wu ◽  
Ju Gong ◽  
Wei Huang ◽  
Qingbing Wang ◽  
Ziyin Wang ◽  
...  
Keyword(s):  
Hepatocellular Carcinoma ◽  
Overall Survival ◽  
Portal Vein ◽  
Tumor Thrombus ◽  
Transcatheter Arterial Chemoembolization ◽  
Main Portal Vein ◽  
Tace Group ◽  
Iodine 125 ◽  
Arterial Chemoembolization

Abstract Background The goal of this study was to compare the clinical results of conventional transcatheter arterial chemoembolization (C-TACE) and doxorubicin-eluting bead transcatheter arterial chemoembolization (D-TACE) combined with endovascular stent implantation with an iodine-125 seed strand in hepatocellular carcinoma (HCC) patients with main portal vein tumor thrombus (MPVTT).Methods This study was a prospective controlled study with follow-up dates spanning from Mar 2015 to Feb 2020. Patients with both HCC and MPVTT were randomly divided into two groups. Portal vein stents with iodine-125 seed strands were implanted first; then, C-TACE or D-TACE was administered to all patients. Objective response rates were assessed. The time to disease progression and survival rate were compared between the two groups.Results A total of 26 patients were enrolled, with 13 in each group. During follow-up, the portal stent patency times were 112.3±98.2 days in the C-TACE group and 101.7±90.4 days in the D-TACE group. The time to disease progression was 42 days in the C-TACE group and 120 days in the D-TACE group (p=0.03). The overall survival time from the first intervention procedure was 216 days in the C-TACE group and 239 days in the D-TACE group (p=0.047). The D-TACE group was superior to the C-TACE group in terms of progression-free survival (PFS) and overall survival (OS) times.Conclusion Endovascular implantation of a stent with an iodine-125 seed strand combined with TACE is safe and effective in HCC patients with MPVTT. Compared to C-TACE, D-TACE achieves more benefits regarding PFS and OS.Trial registration This study was a cohort study, no health-related interventions to evaluate the effects on health outcomes. This study wasn’t a clinical trial.

Sign in / Sign up

Export Citation Format

Share Document